A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

Docetaxel (75 mg m −2 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant toxicity. To verify whether a weekly schedule (33.3 mg m −2 for 6 weeks) improved quality of life (QoL), a phase III study was performed with 220 advanced NSCLC patients,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2004-12, Vol.91 (12), p.1996-2004
Hauptverfasser:	Gridelli, C, Gallo, C, Di Maio, M, Barletta, E, Illiano, A, Maione, P, Salvagni, S, Piantedosi, F V, Palazzolo, G, Caffo, O, Ceribelli, A, Falcone, A, Mazzanti, P, Brancaccio, L, Capuano, M A, Isa, L, Barbera, S, Perrone, F
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Clinical Docetaxel Drug Administration Schedule Drug Resistance Epidemiology Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medical sciences Middle Aged Molecular Medicine Oncology Pneumology Quality of Life Taxoids - administration & dosage Taxoids - adverse effects Treatment Outcome Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!